

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 10-Q

(Address of principal executive offices including
zip code)

Registrant's telephone number, including area code: (512) 942-2935

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a small reporting company) Small reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 8, 2016, the registrant had 13,411,772 shares of common stock, \$0.0001 par value per share, outstanding.

AEGLEA BIOTHERAPEUTICS, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED JUNE 30, 2016

TABLE OF CONTENTS

	Page No.
<u>PART I. FINANCIAL INFORMATION</u>	1
Item 1. <u>Financial Statements (Unaudited)</u>	1
<u>Condensed Consolidated Balance Sheets as of June 30, 2016 and December 31, 2015</u>	1
<u>Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2016 and 2015</u>	2
<u>Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2016 and 2015</u>	3
<u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and 2015</u>	4
<u>Notes to Condensed Consolidated Financial Statements</u>	5
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	17
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	25
Item 4. <u>Controls and Procedures</u>	25
<u>PART II. OTHER INFORMATION</u>	26
Item 1. <u>Legal Proceedings</u>	26
Item 1A. <u>Risk Factors</u>	26
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	56
Item 3. <u>Defaults Upon Senior Securities</u>	56
Item 4. <u>Mine Safety Disclosures</u>	56
Item 5. <u>Other Information</u>	56
Item 6. <u>Exhibits</u>	57
<u>Signatures</u>	58

NOTE ABOUT FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of this Quarterly Report on Form 10-Q. These forward-looking statements may include, but are not limited to, statements regarding our future results of operations and financial position, business strategy, market size, potential growth opportunities, clinical development activities, our ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of clinical trials and potential regulatory approval and commercialization of product candidates. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” and elsewhere in this quarterly report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this quarterly report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations, except as required by law.

As used in this Quarterly Report on Form 10-Q, the terms “Aeglea,” “the Company,” “we,” “us,” and “our” refer to Aeglea BioTherapeutics, Inc. and, where appropriate, its consolidated subsidiaries, unless the context indicates otherwise.

PART I. – FINANCIAL INFORMATION

Item 1. Financial Statements

Aeglea BioTherapeutics, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

	June 30, 2016	December 31, 2015
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	\$ 70,628	\$ 29,294
Marketable securities	2,947	3,768
Restricted cash	155	80
Accounts receivable - grant	1,625	1,697
Deferred offering costs	—	2,535
Prepaid expenses and other current assets	1,551	912
Total current assets	76,906	38,286
Property and equipment, net	377	348
Other non-current assets	18	20
TOTAL ASSETS	\$ 77,301	\$ 38,654
LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)		
CURRENT LIABILITIES		
Accounts payable	\$ 348	\$ 176
Accrued and other current liabilities	3,013	2,347
Total current liabilities	3,361	2,523
Other non-current liabilities	16	27
TOTAL LIABILITIES	3,377	2,550
Commitments and Contingencies (Note 10 and 12)		
Series A convertible preferred stock, \$0.0001 par value; no shares and 2,172,524 shares authorized as of June 30, 2016 and December 31, 2015, respectively; no shares and 2,172,520 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		
	—	13,573
Series B convertible preferred stock, \$0.0001 par value; no shares and 5,008,210 shares authorized as of June 30, 2016 and December 31, 2015, respectively; no shares and 4,999,976 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively		
	—	44,738

of June 30, 2016 and December 31, 2015, respectively

STOCKHOLDERS' EQUITY (DEFICIT)

Preferred stock, \$0.0001 par value; 10,000,000 shares and no shares

authorized as of June 30, 2016 and December 31, 2015, respectively; no

shares issued and outstanding as of June 30, 2016 and December 31,

2015, respectively

— —

Common stock, \$0.0001 par value; 500,000,000 shares and 25,000,000

shares authorized as of June 30, 2016 and December 31, 2015,

respectively; 13,411,772 shares and 757,336 shares issued and

outstanding as of June 30, 2016 and December 31, 2015, respectively

1 —

Additional paid-in capital

107,478 1,373

Accumulated other comprehensive income (loss)

1 (1)

Accumulated deficit

(33,556) (23,579)

TOTAL STOCKHOLDERS' EQUITY (DEFICIT)

73,924 (22,207)

TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND

STOCKHOLDERS' EQUITY (DEFICIT)

\$77,301 \$38,654

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aeglea BioTherapeutics, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2016	2015	2016	2015
Revenues:				
Grant	\$1,373	\$3,427	\$2,232	\$3,427
Operating expenses:				
Research and development	\$4,420	\$2,736	\$8,017	\$4,358
General and administrative	2,448	2,123	4,277	2,970
Total operating expenses	6,868	4,859	12,294	7,328
Loss from operations	(5,495)	(1,432)	(10,062)	(3,901)
Other income (expense):				
Interest income	74	5	100	6
Other expense, net	(9)	—	(15)	—
Total other income (expense)	65	5	85	6
Net loss	\$(5,430)	\$(1,427)	\$(9,977)	\$(3,895)
Deemed dividend to convertible preferred				
Stockholders	—	—	—	(228)
Net loss attributable to common stockholders	\$(5,430)	\$(1,427)	\$(9,977)	\$(4,123)
Net loss per share attributable to common stockholders,				
basic and diluted	\$(0.46)	\$(2.44)	\$(1.61)	\$(7.12)
Weighted-average common shares outstanding,				
basic and diluted	11,776,058	585,798	6,208,379	579,520

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aeglea BioTherapeutics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

	Three Months Ended		Six Months Ended	
	June 30, 2016	2015	June 30, 2016	2015
Net loss	\$ (5,430)	\$ (1,427)	\$ (9,977)	\$ (3,895)
Other comprehensive income (loss):				
Unrealized gain (loss) on marketable securities	(2)	—	2	—
Total comprehensive loss	\$ (5,432)	\$ (1,427)	\$ (9,975)	\$ (3,895)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Aeglea BioTherapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

	Six Months Ended	
	June 30, 2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES		
Net loss	\$(9,977)	\$(3,895)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	62	35
Amortization of premium on marketable securities	14	—
Loss on disposal of property and equipment	—	2
Deferred rent	—	2
Amortization of lease allowance liability	(12)	(12)
Stock-based compensation		